{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:38:43Z","timestamp":1791236323016,"version":"4.1.0"},"reference-count":192,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1\u03b2, IL-6, IL-18, TNF-\u03b1, and IFN-\u03b3. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK\/STAT pathway in COVID-19 as well as the medications used for JAK\/STAT inhibitors.<\/jats:p>","DOI":"10.3389\/fmed.2022.961027","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T05:12:35Z","timestamp":1661836355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy"],"prefix":"10.3389","volume":"9","author":[{"given":"Mansoor","family":"Khaledi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Sameni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Yahyazade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maedeh","family":"Radandish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Owlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Afkhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mahjoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Esmaelpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Kohansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzad","family":"Aghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"B1","article-title":"A review on phylogenetic assessment and cytopathogenesis of filoviruses, retroviruses, and coronaviruses transmitted from bat to human","volume-title":"Cell Mol Res (Iranian J Biol).","author":"Khaledi","year":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.3201\/eid2605.ET2605","article-title":"Etymologia: coronavirus","volume":"26","author":"Henry","year":"2020","journal-title":"Emerg Infect Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42269-020-00341-9","article-title":"An overview on COVID-19: reality and expectation","volume":"44","author":"Hamed","year":"2020","journal-title":"Bull Natl Res Cent."},{"key":"B4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000507423","article-title":"COVID-19 outbreak: an overview","volume":"64","author":"Ciotti","year":"2019","journal-title":"Chemotherapy."},{"key":"B5","unstructured":""},{"key":"B6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.34172\/ijep.2021.14","article-title":"COVID-19 and diabetes: a narrative review","volume":"9","author":"Sameni","year":"2021","journal-title":"Int J Enteric Pathogens."},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.22541\/au.161230839.90084658\/v1","article-title":"COVID-19 coinfection in patients with active tuberculosis: first case-report in Iran","volume-title":"Authorea Preprints.","author":"Fard","year":"2021"},{"key":"B9","doi-asserted-by":"publisher","first-page":"101624","DOI":"10.1016\/j.genrep.2022.101624","article-title":"SARS-CoV-2 and HIV co-infection; clinical features, diagnosis, and treatment strategies: a systematic review and meta-analysis","volume":"27","author":"Dadashi","year":"2022","journal-title":"Gene Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA."},{"key":"B11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S2468-1253(20)30132-1","article-title":"Implications of gastrointestinal manifestations of COVID-19","volume":"5","author":"Yang","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11357-020-00186-0","article-title":"SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes","volume":"42","author":"Nikolich-Zugich","year":"2020","journal-title":"Geroscience."},{"key":"B13","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons\u2013induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe."},{"key":"B14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray Jr","year":"2007","journal-title":"J Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1128\/MMBR.05015-11","article-title":"Into the eye of the cytokine storm","volume":"76","author":"Tisoncik","year":"2012","journal-title":"Microbiol Mol Biol Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40779-020-0233-6","article-title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)","volume":"7","author":"Jin","year":"2020","journal-title":"Mil Med Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","article-title":"COVID-19 with different severities: a multicenter study of clinical features","volume":"201","author":"Feng","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1073\/pnas.1400593111","article-title":"Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection","volume":"111","author":"Teijaro","year":"2014","journal-title":"Proc Nat Acad Sci."},{"key":"B20","first-page":"1216","author":"Ferrara","year":"1993"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1000e131","DOI":"10.4172\/2153-0645.1000e131","article-title":"Clinical preparedness for cytokine storm induced by the highly pathogenic H5N1 influenza virus","volume":"3","author":"Ishikawa","year":"2012","journal-title":"J Pharmacogenom Pharmacoproteomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1086\/649785","article-title":"Cytokine profiles induced by the novel swine-origin influenza A\/H1N1 virus: implications for treatment strategies","volume":"201","author":"Woo","year":"2010","journal-title":"J Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1099\/vir.0.055533-0","article-title":"Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment","volume":"94","author":"Lau","year":"2013","journal-title":"J Gen Virol."},{"key":"B24","first-page":"529","article-title":"Pathogenic human coronavirusinfections: Causes and consequences of cytokine storm and immunopathology","volume-title":"Seminars in Immunopathology","author":"Channappanavar","year":"2017"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1165\/rcmb.2011-0392TR","article-title":"Role of chemokines in the pathogenesis of acute lung injury","volume":"46","author":"Bhatia","year":"2012","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1111\/jth.14818","article-title":"Pulmonary thrombosis in 2019-nCoV pneumonia?","volume":"18","author":"Marongiu","year":"2020","journal-title":"J Thromb Haemost."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7977","DOI":"10.4049\/jimmunol.174.12.7977","article-title":"Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection","volume":"174","author":"Tseng","year":"2005","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","article-title":"Pulmonary pathology of early phase SARS-CoV-2 pneumonia","volume":"15","author":"Tian","year":"2020","journal-title":"J Thorac Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41422-020-0318-5","article-title":"Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient","volume":"30","author":"Yao","year":"2020","journal-title":"Cell Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.CCM.0000149854.61192.DC","article-title":"Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury","volume":"33","author":"Parsons","year":"2005","journal-title":"Crit Care Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.31219\/osf.io\/p69g8","article-title":"Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention","volume":"11","author":"Hussman","year":"2020","journal-title":"Front Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1126\/science.1125676","article-title":"Type 1 interferons and the virus-host relationship: a lesson in detente","volume":"312","author":"Garc\u00eda-Sastre","year":"2006","journal-title":"Science."},{"key":"B36","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle","year":"2020","journal-title":"Autoimmun Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","article-title":"The pathogenesis and treatment of theCytokine Storm'in COVID-19","volume":"80","author":"Ye","year":"2020","journal-title":"J Infect."},{"key":"B38","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science."},{"key":"B39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell Mol Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J Clin Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine."},{"key":"B43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin Exp Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e53725","DOI":"10.7554\/eLife.53725","article-title":"Quantitative analysis of how Myc controls T cell proteomes and metabolic pathways during T cell activation","volume":"9","author":"Marchingo","year":"2020","journal-title":"Elife."},{"key":"B45","doi-asserted-by":"publisher","first-page":"E005","DOI":"10.3760\/cma.j.issn.1001-0939.2020.0005","article-title":"Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia","volume":"43","author":"Chen","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1128\/IAI.72.8.4410-4415.2004","article-title":"Analysis of serum cytokines in patients with severe acute respiratory syndrome","volume":"72","author":"Zhang","year":"2004","journal-title":"Infect Immun."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep25359","article-title":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity","volume":"6","author":"Min","year":"2016","journal-title":"Sci Rep."},{"key":"B48","doi-asserted-by":"crossref","DOI":"10.1101\/2020.04.01.20047381","article-title":"Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients","volume-title":"MedRxiv.","author":"Herold","year":"2020"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2141","article-title":"Interleukin-6 in COVID-19: a systematic review and meta-analysis","volume":"30","author":"Coomes","year":"2020","journal-title":"Rev Med Virol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.medmal.2020.04.002","article-title":"Interleukin-6 as a potential biomarker of COVID-19 progression","volume":"50","author":"Ulhaq","year":"2020","journal-title":"Med Mal Infect."},{"key":"B51","doi-asserted-by":"crossref","DOI":"10.1101\/2020.03.31.019216","article-title":"Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis","volume-title":"BioRxiv.","author":"Li","year":"2020"},{"key":"B52","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaci.2020.05.008","article-title":"Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19","volume":"146","author":"Herold","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao","year":"2020","journal-title":"J Med Virol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00430-006-0019-9","article-title":"Interleukin-6 and its receptor: from bench to bedside","volume":"195","author":"Scheller","year":"2006","journal-title":"Med Microbiol Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphys.2019.00117","article-title":"IL-1\u03b2 and TNF\u03b1 differentially influence NF-\u03baB activity and FasL-induced apoptosis in primary murine hepatocytes during LPS-induced inflammation","volume":"10","author":"Rex","year":"2019","journal-title":"Front Physiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther."},{"key":"B59","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1126\/science.1411569","article-title":"Interleukin-6 and its receptor: a paradigm for cytokines","volume":"258","author":"Kishimoto","year":"1992","journal-title":"Science."},{"key":"B60","doi-asserted-by":"publisher","first-page":"16975","DOI":"10.1073\/pnas.1315862110","article-title":"STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor","volume":"110","author":"Wang","year":"2013","journal-title":"Proc Nat Acad Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2019.03.027","article-title":"Pleiotropy and specificity: insights from the interleukin 6 family of cytokines","volume":"50","author":"Murakami","year":"2019","journal-title":"Immunity."},{"key":"B62","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/pbc.21660","article-title":"Increased serum monocyte chemoattractant protein-1, macrophage inflammatory protein-1\u03b2, and interleukin-8 concentrations in hemophagocytic lymphohistiocytosis","volume":"51","author":"Tamura","year":"2008","journal-title":"Pediatr Blood Cancer."},{"key":"B63","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.4049\/jimmunol.180.11.7102","article-title":"Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells","volume":"180","author":"Briso","year":"2008","journal-title":"J Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/intimm\/dxs158","article-title":"IL-6 amplifier activation in epithelial regions of bronchi after allogeneic lung transplantation","volume":"25","author":"Lee","year":"2013","journal-title":"Int Immunol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.vetimm.2011.07.007","article-title":"Inflammatory cytokines IL-6 and TNF-\u03b1 regulate lymphocyte trafficking through the local lymph node","volume":"144","author":"Wee","year":"2011","journal-title":"Vet Immunol Immunopathol."},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1101\/2020.05.28.20115758","article-title":"An inflammatory cytokine signature helps predict COVID-19 severity and death","volume-title":"medRxiv.","author":"Del Valle","year":"2020"},{"key":"B67","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2005-02-0456","article-title":"IL-6 blocks a discrete early step in lymphopoiesis","volume":"106","author":"Maeda","year":"2005","journal-title":"Blood."},{"key":"B68","doi-asserted-by":"crossref","DOI":"10.1101\/2020.03.27.20045427","article-title":"The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes","volume-title":"MedRxiv.","author":"Feng","year":"2020"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20160417","article-title":"IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21\u2013producing B helper CD8+ T cells","volume":"213","author":"Yang","year":"2016","journal-title":"J Exp Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.4049\/jimmunol.179.4.2041","article-title":"Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+ CD25\u2013 T cells","volume":"179","author":"Dominitzki","year":"2007","journal-title":"J Immunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","article-title":"Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock","volume":"363","author":"Pathan","year":"2004","journal-title":"Lancet."},{"key":"B73","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1021\/pr060665l","article-title":"Tumor necrosis factor-\u03b1-and interleukin-1-induced cellular responses: coupling proteomic and genomic information","volume":"6","author":"Ott","year":"2007","journal-title":"J Proteome Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41590-019-0559-y","article-title":"T cells instruct myeloid cells to produce inflammasome-independent IL-1\u03b2 and cause autoimmunity","volume":"21","author":"Jain","year":"2020","journal-title":"Nat Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fimmu.2020.00211","article-title":"NLRP3 inflammasome\u2014a key player in antiviral responses","volume":"11","author":"Zhao","year":"2020","journal-title":"Front Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3389\/fimmu.2020.583373","article-title":"The inflammasome in times of COVID-19","volume":"11","author":"de Rivero Vaccari","year":"2020","journal-title":"Front Immunol"},{"key":"B79","first-page":"1","article-title":"Neuroimmune signaling: cytokines and the CNS","volume-title":"Neuroscience in the 21st Century","author":"Kennedy","year":"2016"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"Zhou Y-h, Yang Z-q. The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell Mol Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/v12050491","article-title":"ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel?","volume":"12","author":"Xiao","year":"2020","journal-title":"Viruses."},{"key":"B82","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00217.2020","article-title":"COVID-19, ACE2, and the cardiovascular consequences","volume-title":"Am J Physiol Heart Circ Physiol.","author":"South","year":"2020"},{"key":"B83","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/emmm.201000080","article-title":"Angiotensin II revisited: new roles in inflammation, immunology and aging","volume":"2","author":"Benigni","year":"2010","journal-title":"EMBO Mol Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nri2171","article-title":"Evolving functions of endothelial cells in inflammation","volume":"7","author":"Pober","year":"2007","journal-title":"Nat Rev Immunol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41586-020-2588-y","article-title":"Longitudinal analyses reveal immunological misfiring in severe COVID-19","volume":"584","author":"Lucas","year":"2020","journal-title":"Nature."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest."},{"key":"B88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/stem.5530080705","article-title":"The biology of GM-CSF: regulation of production and interaction with its receptor","volume":"8","author":"Griffin","year":"1990","journal-title":"Int J Cell Cloning."},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1101\/2020.02.12.945576","article-title":"Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus","volume-title":"biorxiv.","author":"Zhou","year":"2020"},{"key":"B90","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"B91","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"eabc5367","DOI":"10.1126\/sciimmunol.abc5367","article-title":"HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19","volume":"5","author":"Spinelli","year":"2020","journal-title":"Science Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B94","doi-asserted-by":"crossref","DOI":"10.1101\/2020.04.11.20061473","article-title":"An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area","volume-title":"MedRxiv.","author":"Meng","year":"2020"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","article-title":"Interferon-\u03b12b treatment for COVID-19","volume":"11","author":"Zhou","year":"2020","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S0140-6736(20)30858-8","article-title":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed","volume":"395","author":"Feldmann","year":"2020","journal-title":"Lancet."},{"key":"B97","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1159\/000508247","article-title":"JAK inhibition as a new treatment strategy for patients with COVID-19","volume":"181","author":"Seif","year":"2020","journal-title":"Int Arch Allergy Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"},{"key":"B101","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00134-020-06170-8","article-title":"Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?","volume":"46","author":"Guillon","year":"2020","journal-title":"Intensive Care Med."},{"key":"B103","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/infdis\/jiaa356","article-title":"Attenuated interferon and proinflammatory response in SARS-CoV-2\u2013infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation","volume":"222","author":"Yang","year":"2020","journal-title":"J Infect Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"272359","DOI":"10.1155\/2015\/272359","article-title":"The complex role of STAT3 in viral infections","volume":"2015","author":"Kuchipudi","year":"2015","journal-title":"J Immunol Res"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3389\/fimmu.2019.02590","article-title":"JAK\/STAT cytokine signaling at the crossroad of NK cell development and maturation","volume":"10","author":"Gotthardt","year":"2019","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/eji.202048978","article-title":"Type-I Interferon assessment in 45 minutes using the FilmArray\u00ae PCR platform in SARS-CoV-2 and other viral infections","volume":"51","author":"Mommert","year":"2021","journal-title":"Eur J Immunol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"eabd1554","DOI":"10.1126\/sciimmunol.abd1554","article-title":"Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19","volume":"5","author":"Lee","year":"2020","journal-title":"Science Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","article-title":"Genetic mechanisms of critical illness in Covid-19","volume":"591","author":"Pairo-Castineira","year":"2021","journal-title":"Nature."},{"key":"B109","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity."},{"key":"B110","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of Type I interferon by SARS-CoV-2","volume-title":"Cell Rep.","author":"Xia","year":"2020"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-020-00208-3","article-title":"SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2","volume":"6","author":"Mu","year":"2020","journal-title":"Cell discovery."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41590-019-0466-2","article-title":"Interferon target-gene expression and epigenomic signatures in health and disease","volume":"20","author":"Barrat","year":"2019","journal-title":"Nat Immunol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/genes12020154","article-title":"Epigenetic evolution of ACE2 and IL-6 genes: non-canonical interferon-stimulated genes correlate to COVID-19 susceptibility in vertebrates","volume":"12","author":"Sang","year":"2021","journal-title":"Genes."},{"key":"B114","doi-asserted-by":"publisher","first-page":"11620","DOI":"10.1128\/JVI.00702-07","article-title":"Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain","volume":"81","author":"Wathelet","year":"2007","journal-title":"J Virol."},{"key":"B115","doi-asserted-by":"crossref","DOI":"10.1101\/2020.03.21.001586","article-title":"Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis","volume-title":"BioRxiv.","author":"Sardar","year":"2020"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1080\/22221751.2020.1780953","article-title":"SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists","volume":"9","author":"Yuen","year":"2020","journal-title":"Emerg Microbes Infect."},{"key":"B117","doi-asserted-by":"publisher","first-page":"108185","DOI":"10.1016\/j.celrep.2020.108185","article-title":"SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is increased by a naturally occurring elongation variant","volume":"32","author":"Konno","year":"2020","journal-title":"Cell Rep."},{"key":"B118","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.4049\/jimmunol.1501353","article-title":"Stat1 regulates lupus-like chronic graft-versus-host disease severity via interactions with Stat3","volume":"195","author":"Shao","year":"2015","journal-title":"J Immunol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3389\/fimmu.2019.01448","article-title":"Fine-tuning of type I interferon response by STAT3","volume":"10","author":"Tsai","year":"2019","journal-title":"Front Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.3390\/ijms20194870","article-title":"STAT3 regulates the type I IFN-mediated antiviral response by interfering with the nuclear entry of STAT1","volume":"20","author":"Wang","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B121","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00134-020-06088-1","article-title":"Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19","volume":"46","author":"Joly","year":"2020","journal-title":"Intensive Care Med."},{"key":"B122","doi-asserted-by":"publisher","first-page":"49","DOI":"10.21037\/jlpm.2018.05.03","article-title":"Hyaluronan in acute respiratory distress syndrome (ARDS): simply a biomarker or a deeper insight into ARDS mechanisms","volume":"3","author":"Lonati","year":"2018","journal-title":"J Lab Prec Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41232-020-00146-3","article-title":"How COVID-19 induces cytokine storm with high mortality","volume":"40","author":"Hojyo","year":"2020","journal-title":"Inflamm Regen."},{"key":"B124","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/intimm\/dxq030","article-title":"IL-6: from its discovery to clinical applications","volume":"22","author":"Kishimoto","year":"2010","journal-title":"Int Immunol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.3390\/ijms19113528","article-title":"The two-faced cytokine IL-6 in host defense and diseases","volume":"19","author":"Narazaki","year":"2018","journal-title":"Int J Mol Sci."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(08)60532-5","article-title":"Interleukin-6 in biology and medicine","volume":"54","author":"Akira","year":"1993","journal-title":"Adv Immunol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"a028456","DOI":"10.1101\/cshperspect.a028456","article-title":"Interleukin (IL-6) immunotherapy","volume":"10","author":"Tanaka","year":"2018","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"e20190347","DOI":"10.1084\/jem.20190347","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"J Exp Med"},{"key":"B130","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jmii.2021.05.009","article-title":"Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: a retrospective analysis","volume":"54","author":"P\u00e9rez-Alba","year":"2021","journal-title":"J Microbiol Immunol Infect."},{"key":"B131","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1124\/pr.119.018440","article-title":"Targeting janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution","volume":"72","author":"Bharadwaj","year":"2020","journal-title":"Pharmacol Rev."},{"key":"B132","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"O'shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/jgs.17357","article-title":"Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia","volume":"69","author":"Abizanda","year":"2021","journal-title":"J Am Geriatr Soc."},{"key":"B134","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","article-title":"Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact","volume":"81","author":"Cantini","year":"2020","journal-title":"J Infect."},{"key":"B135","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncolo."},{"key":"B137","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"Proc Nat Acad Sci."},{"key":"B138","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","article-title":"Tocilizumab in patients with severe COVID-19: a retrospective cohort study","volume":"2","author":"Guaraldi","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.reuma.2020.10.009","article-title":"Experience with the use of Baricitinib and tocilizumab monotherapy or combined, in patients with interstitial pneumonia secondary to coronavirus COVID19: a real-world study","volume":"18","author":"Rosas","year":"2020","journal-title":"Reumatol Clin."},{"key":"B140","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N Engl J Med."},{"key":"B141","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med."},{"key":"B142","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cell.2020.11.007","article-title":"Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques","volume":"184","author":"Hoang","year":"2021","journal-title":"Cell"},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.1101\/2020.06.26.20135319","article-title":"Baricitinib restrains the immune dysregulation in COVID-19 patients","volume-title":"medRxiv.","author":"Bronte","year":"2020"},{"key":"B144","doi-asserted-by":"publisher","first-page":"100683","DOI":"10.1016\/j.eclinm.2020.100683","article-title":"Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge","volume":"31","author":"Raman","year":"2021","journal-title":"EClinicalMedicine."},{"key":"B145","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jaci.2020.05.019","article-title":"Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial","volume":"146","author":"Cao","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJMe2034982","article-title":"Baricitinib therapy in COVID-19 pneumonia-an unmet need fulfilled","volume":"384","author":"Goletti","year":"2021","journal-title":"Mass Medical Soc."},{"key":"B147","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16966","article-title":"Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer","volume-title":"Br J Haematol.","author":"Portsmore","year":"2020"},{"key":"B148","doi-asserted-by":"publisher","first-page":"e12697","DOI":"10.15252\/emmm.202012697","article-title":"Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients","volume":"12","author":"Stebbing","year":"2020","journal-title":"EMBO Mol Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ph12010037","article-title":"Baricitinib: a 2018 novel FDA-approved small molecule inhibiting janus kinases","volume":"12","author":"Mayence","year":"2019","journal-title":"Pharmaceuticals."},{"key":"B150","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/art.22890","article-title":"Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal","volume":"57","author":"Schmajuk","year":"2007","journal-title":"Arthritis Care Res."},{"key":"B151","unstructured":""},{"key":"B152","first-page":"318","article-title":"The mechanism of action of tofacitinib-an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N Engl J Med."},{"key":"B154","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izaa303","article-title":"Characteristics and outcomes of IBD patients with COVID-19 on tofacitinib therapy in the SECURE-IBD registry","volume-title":"Inflamm Bowel Dis.","author":"Agrawal","year":"2021"},{"key":"B155","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1111\/jdv.17170","article-title":"Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib","volume":"35","author":"Ferreira","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med."},{"key":"B157","doi-asserted-by":"publisher","first-page":"e002838","DOI":"10.1136\/jitc-2021-002838","article-title":"JAK inhibitors and COVID-19","volume":"10","author":"Levy","year":"2022","journal-title":"J ImmunoThera Cancer."},{"key":"B158","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med."},{"key":"B159","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/ph14070680","article-title":"Current Status of Baricitinib as a Repurposed Therapy for COVID-19","volume":"14","author":"Saber-Ayad","year":"2021","journal-title":"Pharmaceuticals."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06119-2","article-title":"Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh","volume":"21","author":"Hasan","year":"2021","journal-title":"BMC Infect Dis."},{"key":"B161","doi-asserted-by":"crossref","DOI":"10.21203\/rs.3.rs-808746\/v1","article-title":"Single-nucleus lung transcriptomics and inflammatory responses in lethal COVID-19 reveal potential drugs in advanced-stage clinical trials","author":"L\u00f3pez-Cort\u00e9s","year":"2021"},{"key":"B162","doi-asserted-by":"publisher","first-page":"207","DOI":"10.21307\/PM-2020.59.3.15","article-title":"Covid-19 therapy: What have we learned in 8 months?","volume":"59","author":"Adamczyk-Pop\u0142awska","year":"2020","journal-title":"Postepy Mikrobiol."},{"key":"B163","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41592-020-0905-x","article-title":"Cumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus RNA-seq","volume":"17","author":"Li","year":"2020","journal-title":"Nat Methods."},{"key":"B164","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.resinv.2021.07.004","article-title":"Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19","volume":"59","author":"Izumo","year":"2021","journal-title":"Respir Investig."},{"key":"B165","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","article-title":"Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19","volume":"40","author":"Jorgensen","year":"2020","journal-title":"Pharmacotherapy."},{"key":"B166","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2013-02-484832","article-title":"Results of a phase 2 study of pacritinib (SB1518), a JAK2\/JAK2 (V617F) inhibitor, in patients with myelofibrosis","volume":"125","author":"Komrokji","year":"2015","journal-title":"Blood."},{"key":"B167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-016-0367-x","article-title":"Phase 1\/2 study of pacritinib, a next generation JAK2\/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies","volume":"9","author":"Verstovsek","year":"2016","journal-title":"J Hematol Oncol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1073\/pnas.1712452115","article-title":"Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation","volume":"115","author":"Betts","year":"2018","journal-title":"Proc Nat Acad Sci."},{"key":"B169","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e0138","DOI":"10.1097\/CCE.0000000000000138","article-title":"Less can be more when targeting interleukin-6-mediated cytokine release syndrome in coronavirus disease 2019","volume":"2","author":"Betts","year":"2020","journal-title":"Crit Care Explor"},{"key":"B171","doi-asserted-by":"publisher","first-page":"174082","DOI":"10.1016\/j.ejphar.2021.174082","article-title":"Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PLPRO and 3CLPRO proteases","volume":"901","author":"Jade","year":"2021","journal-title":"Eur J Pharmacol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"20587392211036813","DOI":"10.1177\/20587392211036813","article-title":"COVID-19 in a patient with SISTEMIC sclerosis: the role of ruxolitinib","volume":"19","author":"Ucciferri","year":"2021","journal-title":"Eur J Inflammation."},{"key":"B173","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study","volume":"11","author":"Giudice","year":"2020","journal-title":"Front Pharmacol."},{"key":"B174","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16979","article-title":"Ruxolitinib for tocilizumab-refractory severe COVID-19 infection","volume-title":"Br J Haematol.","author":"Innes","year":"2020"},{"key":"B175","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.3390\/jcm10163752","article-title":"JAK inhibition with ruxolitinib in patients with COVID-19 and severe pneumonia: multicenter clinical experience from a compassionate use program in Italy","volume":"10","author":"Vannucchi","year":"2021","journal-title":"J Clin Med."},{"key":"B176","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/ejh.13480","article-title":"Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis","volume":"105","author":"Koschmieder","year":"2020","journal-title":"Eur J Haematol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"e13401","DOI":"10.1111\/tid.13401","article-title":"Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib","volume":"23","author":"Saraceni","year":"2021","journal-title":"Trans Infect Dis."},{"key":"B178","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/2326-6066.CIR-16-0233","article-title":"Human dendritic cells mitigate NK-cell dysfunction mediated by nonselective JAK1\/2 blockade","volume":"5","author":"Curran","year":"2017","journal-title":"Cancer Immunol Res."},{"key":"B179","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res."},{"key":"B180","doi-asserted-by":"crossref","DOI":"10.22541\/au.162560391.18060570\/v1","article-title":"Tofacitinib versus standard of care treatment in patients with COVID-19: a multicenter non-randomized controlled study","volume-title":"Authorea Preprints.","author":"Moiseev","year":"2021"},{"key":"B181","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.mayocpiqo.2021.03.007","article-title":"Anti-inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort","volume":"5","author":"Hayek","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes."},{"key":"B182","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1111\/cts.13123","article-title":"Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19","volume":"14","author":"Pfeifer","year":"2021","journal-title":"Clin Transl Sci."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-020-02387-6","article-title":"Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE)","volume":"23","author":"Kameda","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"B184","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B185","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijid.2020.03.020","article-title":"Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)","volume":"94","author":"Nishiura","year":"2020","journal-title":"Int J Infect Dis."},{"key":"B186","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.medcle.2020.06.026","article-title":"Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection","volume":"155","author":"Reg\u00e1s","year":"2020","journal-title":"Med Clin (Barc)."},{"key":"B187","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/art.40036","article-title":"Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis","volume":"69","author":"Kremer","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B188","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0022-3476(98)70226-4","article-title":"Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a prospective study","volume":"133","author":"Beck","year":"1998","journal-title":"J Pediatr."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1076029619845066","DOI":"10.1177\/1076029619845066","article-title":"Incidence and risk factors of deep vein thrombosis in patients with pelvic and acetabular fractures","volume":"25","author":"Wang","year":"2019"},{"key":"B190","doi-asserted-by":"publisher","first-page":"111532","DOI":"10.1016\/j.colsurfb.2020.111532","article-title":"Controlled release of baricitinib from a thermos-responsive hydrogel system inhibits inflammation by suppressing JAK2\/STAT3 pathway in acute spinal cord injury","volume":"199","author":"Zheng","year":"2021","journal-title":"Colloids Surf B Biointerfaces."},{"key":"B191","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","article-title":"The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation","volume":"34","author":"La Ros\u00e9e","year":"2020","journal-title":"Leukemia."},{"key":"B192","unstructured":"MicromedexI"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.961027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T05:13:09Z","timestamp":1661836389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.961027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":192,"alternative-id":["10.3389\/fmed.2022.961027"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.961027","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"article-number":"961027"}}